Exonhit presents new opportunities in blood diagnostics in neurodegenerative diseases
Identification of new markers for BSE in collaboration with Roche Applied Science
ExonHit applied its DATAS® RNA profiling technology on blood samples from bovines provided by Roche Applied Science and has identified early pre-symptomatic disease markers. The resulting RNA splicing markers were validated with 10 individual whole blood samples of BSE-infected cattle and 10 individual whole blood samples of healthy control animals by two technologically different means: micro array analysis at ExonHit and real-time PCR at Roche with the Roche LightCycler Instrument. Both validation setups revealed the same set of three markers that clearly discriminate between BSE-infected and healthy individuals. ExonHit retains all IP rights on the markers identified and diagnostics use.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.